tigorazan

Tigorazan is a potassium-competitive acid blocker (P-CAB) developed as an oral treatment for gastric acid-related diseases. It acts by directly and reversibly inhibiting the H+/K+-ATPase enzyme in gastric parietal cells, thereby suppressing gastric acid secretion. Unlike traditional proton pump inhibitors (PPIs), which require activation in acidic conditions and are affected by CYP2C19 genetic polymorphisms, P-CABs like tigorazan offer rapid onset of action, strong and sustained acid suppression from the first dose, minimal inter-individual variability, and a longer half-life allowing once-daily dosing. Tigorazan was developed by Roxin Pharmaceutical and is the first domestically self-developed P-CAB approved in China. Its primary indications include gastroesophageal reflux disease (GERD), peptic ulcers, NSAID-associated ulcers, and Helicobacter pylori eradication therapy[3].

Brand names

Tigorazan

Other names

tigorazan